Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hyperinsulinemic-euglycemic Clamp Clear all
Completed Not applicable Interventional Results available

Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus

NCT00943787
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Hyperinsulinemic, euglycemic and hypoglycemic clamp
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2014 · Synced Sep 15, 2026, 4:27 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

NCT06609356
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes, Healthy Volunteer
Interventions
Study Visit 1, Placebo, Study Visit 2, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 15, 2026, 4:27 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Insulin and Muscle Fat Metabolism

NCT04759872
View directory record Official record
Conditions
Overweight and Obesity, Insulin Resistance, Metabolic Disease, Mitochondrial Metabolism, Sedentary Lifestyle
Interventions
Hyperinsulinemic-euglycemic Clamp
Other
Lead sponsor
Oregon State University
Other
Eligibility
30 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metabolomic Analysis of Hepatic Insulin Resistance

NCT01833403
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Hyperinsulinemic-euglycemic clamp
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 15, 2026, 4:27 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

NCT07224334
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 15, 2026, 4:27 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Physical Inactivity and Insulin Resistance in Skeletal Muscle.

NCT00536211
View directory record Official record
Conditions
Metabolic Syndrome X, Insulin Resistance, Hypertension, Hypercholesterolemia, Obesity
Interventions
Exercise, Metformin
Behavioral · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
20 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

The Role of Endocannabinoids in Insulin Production and Action

NCT01517100
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Nabilone, CP-945,598, hyperglycemic clamp, euglycemic-hyperinsulinemic clamp
Other · Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Type 2 Diabetes and the Brain in Adolescents

NCT03461510
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity, Pediatric Obesity, Insulin Resistance, Dysglycemia, Hyperglycemia
Interventions
Hyperglycemic clamp, Hyperinsulinemic Euglycemic clamp
Procedure
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 15, 2026, 4:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of Metabolic Flexibility on Changes in Metabolic Health

NCT06340321
View directory record Official record
Conditions
Obesity, Metabolic Syndrome
Interventions
Metabolic flexibility in the fasted state, Metabolic flexibility in euglycemic-hyperinsulinemic clamp, Metabolic flexibility in the metabolic chamber
Diagnostic Test · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Role of the Omentum in the Treatment of Morbid Obesity

NCT00212160
View directory record Official record
Conditions
Obesity
Interventions
omentectomy
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sympathetic Nerve Activity During Hypoglycemia and Exercise

NCT00608348
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Hyperinsulinemic glucose clamp procedures, moderate exercise
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate

NCT00551564
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
rosiglitazone maleate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

NCT00592332
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, control group
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fatty Acid Oxidation Defects and Insulin Sensitivity

NCT02517307
View directory record Official record
Conditions
Very Long-chain Acyl-CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Normal Volunteers, Carnitine Palmitoyltransferase II Deficiency, Myopathic
Interventions
Intralipid/Heparin, Glycerol/Saline, Hyperinsulinemic euglycemic clamp
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Protection Against Insulin Resistance in Obesity

NCT02717832
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
hyperinsulinemic-euglycemic clamp
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 15, 2026, 4:27 AM EDT
Recruiting Not applicable Interventional

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

NCT07361874
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
Interventions
Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 15, 2026, 4:27 AM EDT
Completed No phase listed Observational

Prediction of ARrhythmic Events With Positron Emission Tomography

NCT01400334
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Hibernating Myocardium, Nerve; Disorder, Sympathetic
Interventions
Positron Emission Tomography
Radiation
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 15, 2026, 4:27 AM EDT
Recruiting Phase 1 Interventional

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

NCT05065372
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions
Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo
Drug
Lead sponsor
Kalie Tommerdahl
Other
Eligibility
12 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 15, 2026, 4:27 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes

NCT04754581
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Maximal ATP Production (ATPmax), Exercise Testing (VO2max), Muscle Biopsy, Adipose Tissue Biopsy, Hyperinsulinemic euglycemic clamp, PET imaging
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
30 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)

NCT02971202
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
Interventions
Hyperinsulinemic, euglycemic clamp, 20% dextrose
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years to 51 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Hypoglycemia and Autonomic Nervous System Function-B

NCT03429946
View directory record Official record
Conditions
Hypoglycemia, Healthy
Interventions
Spironolactone, Placebo, Hypoglycemic Hyperinsulinemic Clamp, Euglycemic Hyperinsulinemic Clamp
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Phase 4 Interventional

Molecular Mechanisms of Type 2 Diabetes Mellitus

NCT00816218
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 15, 2026, 4:27 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Reprometabolic Syndrome Mediates Subfertility in Obesity

NCT02653092
View directory record Official record
Conditions
Obesity, Infertility, Hypogonadotropic Hypogonadotropism, Hyperinsulinemia
Interventions
Insulin, Intralipid, Dextrose, Heparin, GnRH, Hyperinsulinemic Euglycemic Clamp
Drug · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 15, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers

NCT01433705
View directory record Official record
Conditions
Heart Disease
Interventions
Rb-82 Pet scans, F-18 FDG Pet scans, N-13 ammonia Pet scans, Regadenoson
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 15, 2026, 4:27 AM EDT